Arvinas, Inc. (ARVN): EBITDA
-$115.50M
Year ended 2025-12-31
-$15.20M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$115.50M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$245.60M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$396.70M | n/m | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | -$256.90M | n/m | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | -$183.60M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$117.60M | n/c | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$49.90M | n/c | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$43.10M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$24.41M | n/a | 2019-03-26, From 2017-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$115.50M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $74.78M | +491.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $15.06M | -6.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$160.87M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $32.43M | +203.9% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$376.00M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $26.21M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $48.45M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $99.60M | +5.6% |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗